Business Context and Reporting Period
Lantern Pharma Inc. (LTRN), a Delaware corporation, filed this Form 8-K on March 10, 2021. The filing serves as a current report to announce the issuance of a press release and presentation regarding financial and operating results for the fiscal year and fourth quarter ended December 31, 2020.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release (Exhibit 99.1) and presentation (Exhibit 99.2) referenced in the filing but are not detailed in the body of this Form 8-K.
Material Changes
No material changes or comparative financial data are disclosed within the text of this filing. The document solely notifies investors of the upcoming release of results for the period ended December 31, 2020.
Guidance, Outlook, and Risks
The Company scheduled a conference call and live webcast on March 10, 2021, to discuss the financial and operating results. The filing explicitly states that the information in Item 2.02 and Item 7.01, including the referenced exhibits, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section unless expressly incorporated by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for the year ended December 31, 2020.
- Review Exhibit 99.2 (Presentation) for management commentary on clinical progress and future outlook.
- Verify the date and time of the conference call to access live management discussion.
- Note that the financial data in the exhibits is not legally "filed" under Section 18 of the Exchange Act per the language in this 8-K.